UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 15, 2007
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware 1-3619 13-5315170
(State or other (Commission File (I.R.S. Employer
jurisdiction of (Number) Identification No.)
incorporation)
235 East 42nd Street 10017
New York, New York (Zip Code)
(Address of principal executive offices)
Registrant's telephone number, including area code:
(212) 573-2323
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[] Written communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2 (b))
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On October 18, 2007, Pfizer Inc. ("Pfizer") issued a press release and related
materials (collectively, the "October 18, 2007 Press Release") announcing its
financial results for the third quarter of 2007, including charges relating to
its decision to exit Exubera, an inhaled insulin product. The October 18, 2007
Press Release is deemed to be "filed" under the Securities Exchange Act of 1934
as Exhibit 99 to this report and is incorporated herein by reference.
Item 2.05 Costs Associated with Exit or Disposal Activities
On October 15, 2007, the Company made a decision to exit Exubera, an inhaled
insulin product. This decision resulted in total pre-tax charges of $2.8 billion
(including exit costs)in the third quarter of 2007. Additional information
concerning this decision and the related charges is provided in the October 18,
2007 Press Release, which is deemed to be "filed" under the Securities Exchange
Act of 1934 as Exhibit 99 to this report is incorporated by reference herein.
Item 2.06 Material Impairments
On October 15, 2007, the Company made a decision to exit Exubera, an inhaled
insulin product. This decision resulted in total pre-tax charges of $2.8 billion
(including asset impairments) in the third quarter of 2007. Additional
information concerning this decision and the related charges is provided in the
October 18, 2007 Press Release, which is deemed to be "filed" under the
Securities Exchange Act of 1934 as Exhibit 99 to this report is incorporated by
reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit 99 Press Release of Pfizer Inc. dated October 18, 2007, reporting
Pfizer's financial results for the third quarter of 2007,
including charges relating to its decision to exit Exubera, an
inhaled insulin product. Exhibit 99 is deemed to be "filed" under
the Securities Exchange Act of 1934 in this Current Report on
Form 8-K.
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
By: /s/ Margaret M. Foran
----------------------------
Margaret M. Foran
Title: Senior Vice President-Corporate Governance,
Associate General Counsel and Corporate Secretary
Dated: October 18, 2007
EXHIBIT INDEX
Exhibit No. Description
99 Press Release of Pfizer Inc. dated October 18, 2007, reporting
Pfizer's financial results for the third quarter of 2007,
including a charge relating to its decision to exit Exubera, an
inhaled insulin product. Exhibit 99 is deemed to be "filed" under
the Securities Exchange Act of 1934 in this Current Report on
Form 8-K.